Distinguished in Myeloproliferative Neoplasms (MPN)

Kai Wille

Minden, NW, DE 
Distinguished in Myeloproliferative Neoplasms (MPN)
Minden, NW, DE 
OverviewLocationsClinical Research

Overview

Kai Wille practices in Minden, Germany. Wille is rated as a Distinguished expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Their top areas of expertise are Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Polycythemia Vera, and COVID-19.

Their clinical research consists of co-authoring 52 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 10 articles and participated in 2 clinical trials in the study of Myeloproliferative Neoplasms (MPN).

Locations

Minden, NW 32429, Germany
Other Locations
Bochum, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Myeloproliferative Neoplasms (MPN) and COVID-19
Myeloproliferative Neoplasms (MPN) and COVID-19
Enrollment Status: Completed
Publish Date: September 15, 2025
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus
Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2024
Intervention Type: Radiation, Drug
Study Drugs: 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Carboplatin, Paclitaxel
Study Phase: Phase 3
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Other
View 3 Less Clinical Trials

52 Total Publications

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.
Journal: Cancers
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wille's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile